Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives

J Clin Oncol. 2019 Sep 20;37(27):2437-2448. doi: 10.1200/JCO.19.00194. Epub 2019 Aug 12.

Authors

Eric Pujade-Lauraine¹, Susana Banerjee², Sandro Pignata³

Affiliations

¹ ARCAGY-GINECO (Association de Recherche contre les Cancers dont Gynécologiques-Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire, gynécologiques et du sein), Paris, France.
² The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom.
³ Istituto Nazionale Tumori Fondazione G Pascale, Istituto di Ricovero e Cura a Carattere Scientifico, Napoli, Italy.

PMID: 31403868
DOI: 10.1200/JCO.19.00194

No abstract available

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Disease Management
Drug Design
Drug Discovery*
Drug Resistance, Neoplasm / drug effects*
Female
Humans
Neoplasm Recurrence, Local / drug therapy*
Neoplasm Recurrence, Local / pathology
Ovarian Neoplasms / drug therapy*
Ovarian Neoplasms / pathology
Platinum / pharmacology*
Prognosis
Salvage Therapy*

Substances

Antineoplastic Agents
Platinum